CalciTech Receives Technical Due Diligence Report.
HAMILTON, Bermuda--(BUSINESS WIRE)--Nov. 25, 2003
CalciTech Ltd. (OTC BB: CLKTF; TSX: CLK; Freiverkehr: XCH) announced it has received the technical due diligence report carried out by WS Atkins on the process technology for the building of its first 40,000 ton per annum plant for the production of synthetic calcium carbonate (SCC). The report supports CalciTech's planned project finance by providing a third party endorsement of the technology and engineering side of the project and by confirming that the requirements for scaling up to this first SCC plant are satisfied
Christoph Jensen, Project Director, responsible for the building of the commercial-scale merchant plant and Manager of the small-scale production plant stated, "The report is a clear third party endorsement of our technology. With the know-how we have gained in the scale up process to and the operation of our small-scale plant, we are now ready to build the commercial-scale plant."
Roger Leopard, CEO of CalciTech, stated, "These findings are as we expected, and another important ingredient in our path toward successful conclusion of project finance for our first merchant plant."
For More Information, visit www.CalciTech.com.
This press release contains forward-looking statements which are subject to a number of contingencies and uncertainties, including but not limited to, market acceptance for CalciTech products, manufacturing of CalciTech products in a commercial setting, obtaining adequate financing and construction management for products and obtaining appropriate permits. Such forward-looking statements are not guarantees of future performance, and are based on numerous assumptions about future conditions that could change.
No Stock Exchange has reviewed or accepted responsibility for the adequacy or accuracy of this press release.
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 25, 2003|
|Previous Article:||Bridges to Excellence Coalition Issues First Bonus Payments to Doctors for Exemplary Diabetes Care.|
|Next Article:||Nanobac Pharmaceuticals, Inc. Announces the Much Anticipated Release of `Has Heart Disease Been Cured?'.|